Silvana Mouron

Silvana Mouron

Auto-generated profile, based on publicly available information

Silvana Mouron

Centro de Investigaciones Biológicas; Consejo Superior de Investigaciones Científicas; Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER); Madrid, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Autophagy
Verified
Journal Article
Closed access
PDF file
EKErwin Knecht
Erwin Knecht
OCOlga Criado-García
Olga Criado-García
CACarmen Aguado
Carmen Aguado
JGJavier Gayarre
Javier Gayarre
LDLara Duran-Trio
Lara Duran-Trio
SCSantiago Rodríguez De Córdoba
Santiago Rodríguez De Córdoba
Lafora disease (LD), a fatal neurodegenerative disorder characterized by intracellular inclusions called Lafora bodies (LBs), is caused by recessive loss-of-function mutations in the genes encoding either laforin or malin. Previous studies suggested a role of these proteins in regulating glycogen biosynthesis, in glycogen dephosphorylation and in the modulation of intracellular proteolytic systems. However, the contribution of each of these processes to LD pathogenesis is unclear. Here we review our recent finding that dysfunction of autophagy is a common feature of both laforin- and malin-deficient mice, preceding other pathological manifestations. We propose that autophagy plays a primary role in LD pathogenesis and is a potential target for its treatment.

24 May 2019 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
MQMiguel Quintela-Fandino
Miguel Quintela-Fandino
JAJuan V. Apala
Juan V. Apala
DMDiego Malon
Diego Malon
SMSilvana Mouron
Silvana Mouron
JHJavier Hornedo
Javier Hornedo
JGJuan Guerra
Juan Guerra
The combined use of a FGFR1 blocker and aromatase inhibitors is appealing for treating breast cancer patients with FGFR1 amplification. However, no pharmacodynamic studies have addressed the effects of this combined target modulation. We conducted a phase 0/I clinical trial in an adjuvant setting, with the goal of obtaining pharmacodynamic proof of the effects of combined aromatase and FGFR1 inhibition and to establish the RP2D for nintedanib combined with letrozole. Women with early-stage luminal breast cancer were eligible for enrollment in the study. Dose level 1 was nintedanib (150 mg/bid) plus letrozole (2.5 mg/day) administered for a single 28-day cycle (DLT assessment period), followed by a classic 3 + 3 schedule. FGF23 and 17-B-estradiol levels were determined on days 0 and 15; pharmacokinetic parameters were assessed on days 1 and 28. Patients were allowed to continue treatment for 6 cycles. The primary study endpoint was a demonstration of FGFR1 modulation (defined as a 25% increase in the plasma FGF23 level). A total of 19 patients were enrolled in the study (10 in the expansion cohort following dose escalation). At the RP2D (nintedanib 200 mg/bid plus letrozole 2.5 mg/day), we observed a 55% mean increase in the plasma FGF23 level, and 81.2% of the patients had no detectable level of 17-B-estradiol in their plasma (87.5% of the patients treated with letrozole alone). Nintedanib and letrozole displayed a pharmacokinetic interaction that led to three- and twofold increases in their respective plasma concentrations. Most G3 toxic events (5 out of 6: 2 diarrhea and 3 hypertransaminasemia) occurred subsequent to the DLT assessment period. Combined treatment with nintedanib (200 mg/bid) plus letrozole (2.5 mg/day) effectively suppressed FGFR1 and aromatase activity, and these respective doses can be used as starting doses in any subsequent trials. However, drug-drug interactions may produce tolerability issues when these drugs are co-administered for an extended time period (e.g., 6 months). Patients enrolled in future trials with these drugs should be carefully monitored for their FGF23 levels and signs of toxicity, and those findings should guide individualized treatment decisions. This trial was registered at www.clinicaltrials.gov under reg. # NCT02619162, on December 2, 2015.

8 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LDLiany Luna Dulcey
Liany Luna Dulcey
JSJames Almada Da Silva
James Almada Da Silva
VJVeronica Jimenez-Renard
Veronica Jimenez-Renard
ECEduardo Caleiras
Eduardo Caleiras
SMSilvana Mouron
Silvana Mouron
MARCIA COMINETTIMARCIA COMINETTI
MARCIA COMINETTI
Breast cancer metastasis is the most common cause of cancer death in women worldwide. Triple-negative breast cancers (TNBC) form a heterogeneous group of tumors that have higher relapse rates and poorer survival compared to other breast cancer subtypes. Thus, this work reports the antitumor and antimetastatic activities of a [6]-gingerol-derived semi-synthetic compound named SSi6 on MDA-MB-231 TNBC cells using xenograft models. SSi6 did not cause toxic effects in vivo as demonstrated by body weight and hematological and histological evaluations. From the orthotopic xenograft model, we demonstrated that SSi6 slows and inhibits the growth of the primary tumor, as well as prevents metastatic spontaneous progression from lymph nodes to the lungs. Moreover, a second xenograft model with resection of the primary tumor showed that SSi6 also blocks the progression of metastases from the lymph nodes to other visceral organs. Taken together, our results demonstrate that SSi6 is a promising compound to be investigated in other preclinical and clinical models to be applied as a complementary therapy for TNBC.

2 June 2026 in Journal of Clinical Investigation
Verified
Journal Article
Open access
JRJose Luis Ruiz-Sepulveda
Jose Luis Ruiz-Sepulveda
MBMaria J. Bueno
Maria J. Bueno
SMSilvana Mouron
Silvana Mouron
VJVeronica Jimenez-Renard
Veronica Jimenez-Renard
MMManuel Muñoz
Manuel Muñoz
MQMiguel Quintela-Fandino
Miguel Quintela-Fandino
Resistance to antiangiogenics is a major challenge in cancer therapy. These agents can either normalize or exacerbate tumor vascular abnormality and hypoxia. The mechanisms of resistance remain unclear in the latter setting. By integrating data from mouse models and clinical trials, we showed that hypoxia-inducing anti-VEGF therapy upregulated programmed cell death ligand 1 (PD-L1), yet failed to sensitize tumors to PD-L1 blockade. Mechanistically, early hypoxic stress triggered epithelial osteopontin (SPP1) production, which recruited monocytes and skewed macrophages toward M2 states, suppressing T cell cytotoxicity. Pharmacological SPP1 depletion impeded the development of hypoxia, reduced M2 infiltration, restored T cell activity, and enabled synergy between antiangiogenics and anti–PD-L1. Genetic dissection — tumor-epithelial Spp1 -KO grafts and bone marrow chimeras generated by lethal irradiation and reconstitution with Spp1 –/– or WT hematopoietic donors — showed that myeloid SPP1 contributed only marginally compared with epithelial SPP1. These findings identified SPP1 as a central mediator of resistance to hypoxia-inducing antiangiogenics, contributed to a comprehensive model of antiangiogenic resistance, and supported SPP1-targeted strategies to personalize immunotherapy and antiangiogenic therapy according to tumor hypoxia.

13 July 2012 in Autophagy
Verified
Journal Article
Open access
PDF file
EKErwin Knecht
Erwin Knecht
OCOlga Criado-García
Olga Criado-García
CACarmen Aguado
Carmen Aguado
JGJavier Gayarre
Javier Gayarre
LDLara Duran-Trio
Lara Duran-Trio
SCSantiago Rodríguez De Córdoba
Santiago Rodríguez De Córdoba